首页 > 最新文献

JAMA dermatology最新文献

英文 中文
Precocious Puberty Among Children and Adolescents With Hidradenitis Suppurativa. 患有化脓性扁桃体炎的儿童和青少年中的性早熟。
IF 11.5 1区 医学 Q1 DERMATOLOGY Pub Date : 2024-11-01 DOI: 10.1001/jamadermatol.2024.3104
Nicole Mastacouris, Bria Midgette, Andrew Strunk, Amit Garg
{"title":"Precocious Puberty Among Children and Adolescents With Hidradenitis Suppurativa.","authors":"Nicole Mastacouris, Bria Midgette, Andrew Strunk, Amit Garg","doi":"10.1001/jamadermatol.2024.3104","DOIUrl":"10.1001/jamadermatol.2024.3104","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"1245-1246"},"PeriodicalIF":11.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11411440/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142287610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Application of New Risk-Based Cancer Screening in Patients With Dermatomyositis. 基于风险的新型癌症筛查在皮肌炎患者中的临床应用。
IF 11.5 1区 医学 Q1 DERMATOLOGY Pub Date : 2024-11-01 DOI: 10.1001/jamadermatol.2024.3349
Andrea D Maderal, Alisa Femia
{"title":"Clinical Application of New Risk-Based Cancer Screening in Patients With Dermatomyositis.","authors":"Andrea D Maderal, Alisa Femia","doi":"10.1001/jamadermatol.2024.3349","DOIUrl":"10.1001/jamadermatol.2024.3349","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"1151-1152"},"PeriodicalIF":11.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142346990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dermatology Encounters After Solid Organ Transplant. 实体器官移植后的皮肤病治疗。
IF 11.5 1区 医学 Q1 DERMATOLOGY Pub Date : 2024-11-01 DOI: 10.1001/jamadermatol.2024.3173
Surya A Veerabagu, Kai-Ping Liao, Anokhi Jambusaria-Pahlajani, Lee Wheless, Mackenzie R Wehner
{"title":"Dermatology Encounters After Solid Organ Transplant.","authors":"Surya A Veerabagu, Kai-Ping Liao, Anokhi Jambusaria-Pahlajani, Lee Wheless, Mackenzie R Wehner","doi":"10.1001/jamadermatol.2024.3173","DOIUrl":"10.1001/jamadermatol.2024.3173","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"1246-1248"},"PeriodicalIF":11.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11425182/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142346991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment of Annular Elastolytic Giant Cell Granuloma With Tofacitinib. 托法替尼治疗环状溶解性巨细胞肉芽肿
IF 11.5 1区 医学 Q1 DERMATOLOGY Pub Date : 2024-11-01 DOI: 10.1001/jamadermatol.2024.3435
Tian-Yi Zhang, Tao Qu
{"title":"Treatment of Annular Elastolytic Giant Cell Granuloma With Tofacitinib.","authors":"Tian-Yi Zhang, Tao Qu","doi":"10.1001/jamadermatol.2024.3435","DOIUrl":"10.1001/jamadermatol.2024.3435","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"1252-1254"},"PeriodicalIF":11.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142346996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Primary Cutaneous Nocardiosis. 原发性皮肤诺卡氏杆菌病
IF 11.5 1区 医学 Q1 DERMATOLOGY Pub Date : 2024-11-01 DOI: 10.1001/jamadermatol.2024.3834
Mingjia Hu, Fangfang Bao, Furen Zhang
{"title":"Primary Cutaneous Nocardiosis.","authors":"Mingjia Hu, Fangfang Bao, Furen Zhang","doi":"10.1001/jamadermatol.2024.3834","DOIUrl":"10.1001/jamadermatol.2024.3834","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"1237-1238"},"PeriodicalIF":11.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142361539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Errors in Figures 1 and 3. 图 1 和图 3 中的误差。
IF 11.5 1区 医学 Q1 DERMATOLOGY Pub Date : 2024-11-01 DOI: 10.1001/jamadermatol.2024.4370
{"title":"Errors in Figures 1 and 3.","authors":"","doi":"10.1001/jamadermatol.2024.4370","DOIUrl":"10.1001/jamadermatol.2024.4370","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"1257"},"PeriodicalIF":11.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11465116/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142390627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cost and Cost-Effectiveness of the Management Strategies of Chronic Urticaria: A Systematic Review. 慢性荨麻疹治疗策略的成本和成本效益:系统综述。
IF 11.5 1区 医学 Q1 DERMATOLOGY Pub Date : 2024-11-01 DOI: 10.1001/jamadermatol.2024.2863
Surapon Nochaiwong, Mati Chuamanochan, Chidchanok Ruengorn, Ratanaporn Awiphan, Jonathan A Bernstein, Kednapa Thavorn

Importance: Although treatment for chronic urticaria (CU) has improved over the past decades, evidence regarding costs and net benefits associated with these treatment strategies have yet to be comprehensively characterized and synthesized.

Objective: To summarize the cost and cost-effectiveness of CU management strategies.

Evidence review: An extensive systematic literature search of 6 databases (MEDLINE, Embase, PubMed Cochrane, Scopus, and CINAHL) and gray literature sources, without language restriction, was conducted and updated to March 23, 2024. Articles that performed cost analysis or full economic evaluation among patients with CU were included. Two reviewers independently extracted data, such as annual costs of health care services or incremental cost-effectiveness ratio (ICER) per quality-adjusted life-year (QALY). All monetary values were converted and inflated to 2023 US dollars. Evidence-based synthesis for health benefit was judged using the Evidence Rating Matrix by the Institute for Clinical and Economic Review.

Findings: Seventeen unique studies (11 cost analysis studies and 6 full economic evaluations) were included. With the wide variation in health care resources, services that included biologic omalizumab utilization had higher annual health care cost estimations for CU management than services that did not include omalizumab prescription (median [IQR] cost, $6933 [$5988-$8717] vs $5621 [$2488-$8754]). The biologic omalizumab, 300 mg, for H1 antihistamine-refractory chronic spontaneous urticaria (CSU) (3 studies) was found to have a median (IQR) ICER of $89 005 ($36 058-$145 694) per QALY (evidence rating as incremental or better; moderate certainty with substantial net health benefit). Routine laboratory testing among patients with CSU with otherwise normal histories and physical examination findings (1 study) had ICERs ranging from $1 427 928 to $1 950 524 per QALY (evidence rating as comparable or inferior; moderate certainty that the net health benefit is inferior).

Conclusions and relevance: With limited evidence of cost-effectiveness, biologic omalizumab, 300 mg, for H1 antihistamine-refractory CSU was found to be cost-effective in US health care services at the willingness to pay threshold of $150 000 per QALY. Meanwhile, routine laboratory testing among patients with CSU without compelling indication was not cost-effective. Future studies in more diverse CU populations and resource settings are needed to fill evidence gaps.

重要性:尽管慢性荨麻疹(CU)的治疗在过去几十年中有所改善,但与这些治疗策略相关的成本和净效益方面的证据尚未得到全面描述和综合:目的:总结慢性荨麻疹治疗策略的成本和成本效益:对 6 个数据库(MEDLINE、Embase、PubMed Cochrane、Scopus 和 CINAHL)和灰色文献来源进行了广泛的系统性文献检索,无语言限制,并更新至 2024 年 3 月 23 日。研究纳入了对 CU 患者进行成本分析或全面经济评估的文章。两名审稿人独立提取数据,如医疗服务的年度成本或每质量调整生命年(QALY)的增量成本效益比(ICER)。所有货币价值均换算成 2023 年的美元。采用临床与经济审查研究所的证据评级矩阵对健康效益的循证综述进行评判:共纳入 17 项独特的研究(11 项成本分析研究和 6 项全面经济评估)。由于医疗资源的差异很大,与不包括奥马珠单抗处方的服务相比,包括使用生物制剂奥马珠单抗的服务在CU管理方面的年度医疗成本估算更高(中位数[IQR]成本,6933美元[5988-8717美元] vs 5621美元[2488-8754美元])。针对 H1 抗组胺药难治性慢性自发性荨麻疹(CSU)的生物制剂奥马珠单抗(300 毫克)(3 项研究)的每 QALY ICER 中位数(IQR)为 89 005 美元(36 058 美元-145 694 美元)(证据评级为增量或更好;中度确定性,具有可观的净健康获益)。在病史和体格检查结果正常的 CSU 患者中进行常规实验室检测(1 项研究),每 QALY 的 ICER 为 1 427 928 美元至 1 950 524 美元(证据评级为相当或较差;中度确定净健康获益较差):在成本效益证据有限的情况下,生物制剂奥马珠单抗(300 毫克)治疗 H1 抗组胺药难治性 CSU 在美国医疗保健服务中的成本效益为每 QALY 150 000 美元的支付意愿阈值。与此同时,对无明确适应症的 CSU 患者进行常规实验室检测并不划算。未来需要对更多不同的CU人群和资源环境进行研究,以填补证据空白。
{"title":"Cost and Cost-Effectiveness of the Management Strategies of Chronic Urticaria: A Systematic Review.","authors":"Surapon Nochaiwong, Mati Chuamanochan, Chidchanok Ruengorn, Ratanaporn Awiphan, Jonathan A Bernstein, Kednapa Thavorn","doi":"10.1001/jamadermatol.2024.2863","DOIUrl":"10.1001/jamadermatol.2024.2863","url":null,"abstract":"<p><strong>Importance: </strong>Although treatment for chronic urticaria (CU) has improved over the past decades, evidence regarding costs and net benefits associated with these treatment strategies have yet to be comprehensively characterized and synthesized.</p><p><strong>Objective: </strong>To summarize the cost and cost-effectiveness of CU management strategies.</p><p><strong>Evidence review: </strong>An extensive systematic literature search of 6 databases (MEDLINE, Embase, PubMed Cochrane, Scopus, and CINAHL) and gray literature sources, without language restriction, was conducted and updated to March 23, 2024. Articles that performed cost analysis or full economic evaluation among patients with CU were included. Two reviewers independently extracted data, such as annual costs of health care services or incremental cost-effectiveness ratio (ICER) per quality-adjusted life-year (QALY). All monetary values were converted and inflated to 2023 US dollars. Evidence-based synthesis for health benefit was judged using the Evidence Rating Matrix by the Institute for Clinical and Economic Review.</p><p><strong>Findings: </strong>Seventeen unique studies (11 cost analysis studies and 6 full economic evaluations) were included. With the wide variation in health care resources, services that included biologic omalizumab utilization had higher annual health care cost estimations for CU management than services that did not include omalizumab prescription (median [IQR] cost, $6933 [$5988-$8717] vs $5621 [$2488-$8754]). The biologic omalizumab, 300 mg, for H1 antihistamine-refractory chronic spontaneous urticaria (CSU) (3 studies) was found to have a median (IQR) ICER of $89 005 ($36 058-$145 694) per QALY (evidence rating as incremental or better; moderate certainty with substantial net health benefit). Routine laboratory testing among patients with CSU with otherwise normal histories and physical examination findings (1 study) had ICERs ranging from $1 427 928 to $1 950 524 per QALY (evidence rating as comparable or inferior; moderate certainty that the net health benefit is inferior).</p><p><strong>Conclusions and relevance: </strong>With limited evidence of cost-effectiveness, biologic omalizumab, 300 mg, for H1 antihistamine-refractory CSU was found to be cost-effective in US health care services at the willingness to pay threshold of $150 000 per QALY. Meanwhile, routine laboratory testing among patients with CSU without compelling indication was not cost-effective. Future studies in more diverse CU populations and resource settings are needed to fill evidence gaps.</p>","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"1225-1236"},"PeriodicalIF":11.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142080298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Estimating Costs in Beremagene Geperpavec for Dystrophic Epidermolysis Bullosa-Reply. 估算Beremagene Geperpavec治疗营养不良性表皮松解症的成本。
IF 11.5 1区 医学 Q1 DERMATOLOGY Pub Date : 2024-11-01 DOI: 10.1001/jamadermatol.2024.2970
Adam J N Raymakers, Aaron S Kesselheim, William B Feldman
{"title":"Estimating Costs in Beremagene Geperpavec for Dystrophic Epidermolysis Bullosa-Reply.","authors":"Adam J N Raymakers, Aaron S Kesselheim, William B Feldman","doi":"10.1001/jamadermatol.2024.2970","DOIUrl":"10.1001/jamadermatol.2024.2970","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"1255"},"PeriodicalIF":11.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142287608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bullous Pemphigoid Severity and Levels of Antibodies to BP180 and BP230: A Systematic Review and Meta-Analysis. 大疱性类天疱疮的严重程度与 BP180 和 BP230 的抗体水平:系统回顾与元分析》。
IF 11.5 1区 医学 Q1 DERMATOLOGY Pub Date : 2024-11-01 DOI: 10.1001/jamadermatol.2024.3425
Po-Yi Chou, Chia-Ling Yu, Chiao-Ni Wen, Yu-Kang Tu, Ching-Chi Chi

Importance: The correlation between serum levels of autoantibodies against bullous pemphigoid (BP) antigens 180 (BP180) and 230 (BP230) with BP disease severity is unclear.

Objective: To investigate the correlation of anti-BP180 and anti-BP230 immunoglobulin G (IgG) antibody levels with BP disease severity.

Data sources: A search was performed of the Cochrane Central Register of Controlled Trials, Embase, and PubMed databases from their respective inception to April 11, 2024.

Study selection: Studies evaluating the correlation between serum levels of anti-BP180 or anti-BP230 IgG measured using enzyme-linked immunosorbent assay (ELISA) and disease severity assessed per the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) or BP Disease Area Index (BPDAI) were included. No language or geographic restrictions were imposed. Nearly 0.4% of initially identified studies met the selection criteria.

Data extraction and synthesis: One researcher extracted data and another researcher confirmed data. The risk of bias was independently assessed by these researchers using the Quality Assessment of Diagnostic Accuracy Studies 2 tool, with discrepancies resolved by discussion with a third researcher. A random-effects model meta-analysis and a subgroup analysis were conducted based on the ELISA kit manufacturers.

Main outcomes and measures: Pooled correlation coefficients of antibody levels with ABSIS and BPDAI.

Results: In all, 14 studies with 1226 participants were analyzed. The risk of bias of included studies was generally low. The meta-analysis found anti-BP180 autoantibody levels showed moderate correlation with objective BPDAI (r = 0.56; 95% CI, 0.46-0.64) at baseline, strong correlation (r = 0.63; 95% CI, 0.39-0.79) at 3-month follow-up, and moderate correlation (r = 0.53; 95% CI, 0.25-0.72) at 6-month follow-up. Anti-BP180 autoantibody levels also showed moderate correlation (r = 0.52; 95% CI, 0.39-0.62) with ABSIS at baseline, strong correlation (r = 0.62; 95% CI, 0.39-0.79) at 3-month follow-up, and moderate correlation (r = 0.53; 95% CI, 0.25-0.72) at 6-month follow-up. By contrast, anti-BP230 autoantibody levels showed no association with objective BPDAI and ABSIS at diagnosis and follow-up. The subgroup analysis found similar results when using different ELISA kits.

Conclusions and relevance: The findings of this systematic review and meta-analysis indicated that anti-BP180 autoantibody levels may serve as an adjunctive tool for monitoring BP disease severity and guiding clinical care for patients with BP.

重要性:针对大疱性类天疱疮(BP)抗原180(BP180)和230(BP230)的血清自身抗体水平与BP疾病严重程度之间的相关性尚不明确:研究抗 BP180 和抗 BP230 免疫球蛋白 G (IgG) 抗体水平与 BP 疾病严重程度的相关性:研究选择:研究筛选:纳入了评估使用酶联免疫吸附试验(ELISA)测定的血清抗 BP180 或抗 BP230 IgG 水平与根据自身免疫性大疱性皮肤病强度评分(ABSIS)或 BP 疾病面积指数(BPDAI)评估的疾病严重程度之间相关性的研究。没有语言或地域限制。在初步确定的研究中,近 0.4% 的研究符合筛选标准:一名研究人员提取数据,另一名研究人员确认数据。偏倚风险由这些研究人员使用诊断准确性研究质量评估 2 工具进行独立评估,不一致之处由第三位研究人员讨论解决。根据ELISA试剂盒生产商进行了随机效应模型荟萃分析和亚组分析:抗体水平与 ABSIS 和 BPDAI 的汇总相关系数:结果:共分析了14项研究,1226名参与者。纳入研究的偏倚风险普遍较低。荟萃分析发现,抗 BP180 自身抗体水平与客观 BPDAI 在基线时呈中度相关(r = 0.56;95% CI,0.46-0.64),在 3 个月随访时呈强相关(r = 0.63;95% CI,0.39-0.79),在 6 个月随访时呈中度相关(r = 0.53;95% CI,0.25-0.72)。抗 BP180 自身抗体水平在基线时与 ABSIS 也呈中度相关(r = 0.52;95% CI,0.39-0.62),随访 3 个月时呈强相关(r = 0.62;95% CI,0.39-0.79),随访 6 个月时呈中度相关(r = 0.53;95% CI,0.25-0.72)。相比之下,抗 BP230 自身抗体水平与诊断和随访时的客观 BPDAI 和 ABSIS 没有关联。亚组分析发现,使用不同的酶联免疫吸附试剂盒得出的结果相似:本系统综述和荟萃分析的结果表明,抗 BP180 自身抗体水平可作为监测 BP 疾病严重程度和指导 BP 患者临床治疗的辅助工具。
{"title":"Bullous Pemphigoid Severity and Levels of Antibodies to BP180 and BP230: A Systematic Review and Meta-Analysis.","authors":"Po-Yi Chou, Chia-Ling Yu, Chiao-Ni Wen, Yu-Kang Tu, Ching-Chi Chi","doi":"10.1001/jamadermatol.2024.3425","DOIUrl":"10.1001/jamadermatol.2024.3425","url":null,"abstract":"<p><strong>Importance: </strong>The correlation between serum levels of autoantibodies against bullous pemphigoid (BP) antigens 180 (BP180) and 230 (BP230) with BP disease severity is unclear.</p><p><strong>Objective: </strong>To investigate the correlation of anti-BP180 and anti-BP230 immunoglobulin G (IgG) antibody levels with BP disease severity.</p><p><strong>Data sources: </strong>A search was performed of the Cochrane Central Register of Controlled Trials, Embase, and PubMed databases from their respective inception to April 11, 2024.</p><p><strong>Study selection: </strong>Studies evaluating the correlation between serum levels of anti-BP180 or anti-BP230 IgG measured using enzyme-linked immunosorbent assay (ELISA) and disease severity assessed per the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) or BP Disease Area Index (BPDAI) were included. No language or geographic restrictions were imposed. Nearly 0.4% of initially identified studies met the selection criteria.</p><p><strong>Data extraction and synthesis: </strong>One researcher extracted data and another researcher confirmed data. The risk of bias was independently assessed by these researchers using the Quality Assessment of Diagnostic Accuracy Studies 2 tool, with discrepancies resolved by discussion with a third researcher. A random-effects model meta-analysis and a subgroup analysis were conducted based on the ELISA kit manufacturers.</p><p><strong>Main outcomes and measures: </strong>Pooled correlation coefficients of antibody levels with ABSIS and BPDAI.</p><p><strong>Results: </strong>In all, 14 studies with 1226 participants were analyzed. The risk of bias of included studies was generally low. The meta-analysis found anti-BP180 autoantibody levels showed moderate correlation with objective BPDAI (r = 0.56; 95% CI, 0.46-0.64) at baseline, strong correlation (r = 0.63; 95% CI, 0.39-0.79) at 3-month follow-up, and moderate correlation (r = 0.53; 95% CI, 0.25-0.72) at 6-month follow-up. Anti-BP180 autoantibody levels also showed moderate correlation (r = 0.52; 95% CI, 0.39-0.62) with ABSIS at baseline, strong correlation (r = 0.62; 95% CI, 0.39-0.79) at 3-month follow-up, and moderate correlation (r = 0.53; 95% CI, 0.25-0.72) at 6-month follow-up. By contrast, anti-BP230 autoantibody levels showed no association with objective BPDAI and ABSIS at diagnosis and follow-up. The subgroup analysis found similar results when using different ELISA kits.</p><p><strong>Conclusions and relevance: </strong>The findings of this systematic review and meta-analysis indicated that anti-BP180 autoantibody levels may serve as an adjunctive tool for monitoring BP disease severity and guiding clinical care for patients with BP.</p>","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"1192-1200"},"PeriodicalIF":11.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11447634/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142361533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Perianal Paget Disease. 肛周胬肉病
IF 11.5 1区 医学 Q1 DERMATOLOGY Pub Date : 2024-11-01 DOI: 10.1001/jamadermatol.2024.4172
Jiang-Wei Cheng, Bo-Wen Zheng, Jiu-Hong Li
{"title":"Perianal Paget Disease.","authors":"Jiang-Wei Cheng, Bo-Wen Zheng, Jiu-Hong Li","doi":"10.1001/jamadermatol.2024.4172","DOIUrl":"10.1001/jamadermatol.2024.4172","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"1239-1240"},"PeriodicalIF":11.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142465897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
JAMA dermatology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1